There is new hope for the millions of patients who develop cancer each year. The study showed that vaccines based on the tumors of patients protect these people from later cancer recurrence.
Vaccines made individually for each patient based on their tumors have shown promising results in clinical trials. They involved 8 victims of malignant neoplasms of the head and neck, who had the highest risk of recurrence. No one's cancer returned four months after vaccination, although without these vaccinations, the chances of this occurring were quite high. In comparison, two patients in the control group who did not receive these shots experienced the same relapses.
Stem cells cure epilepsy
This vaccine uses the same technology as AstraZeneca's coronavirus shot – it's based on DNA taken from each patient's tumor. This genetic code is then placed into a weakened virus, which is used to deliver the material into the body. Thus, the immune system is trained to recognize and fight cancer if it starts to return.
If detected early, kidney cancer is successfully treated
The vaccine was injected weekly for a month and a half, after which patients received booster doses every three weeks for a year. True, only a few people took part in the study, and this is clearly not enough to draw far-reaching conclusions. But scientists argue that all available information points to movement in the right direction. (READ MORE)